Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase
- 1 January 1994
- book chapter
- Published by Springer Nature
- Vol. 71, 161-191
- https://doi.org/10.1007/978-1-4615-2592-9_9
Abstract
No abstract availableKeywords
This publication has 109 references indexed in Scilit:
- A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell linesInternational Journal of Cancer, 1992
- c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinomaJournal of Hepatology, 1992
- Identification and interpretation of epidermal growth factor and c-erbB-2 overexpressionEuropean Journal Of Cancer, 1992
- Isolation and characterization of a neu protein-specific activating factor from human ATL-2 cell conditioned mediumBiochemical and Biophysical Research Communications, 1991
- Long‐term survival in breast cancer related to overexpression of the c‐erbB‐2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL‐CB11The Journal of Pathology, 1991
- Differentiation of cultured human breast cancer cells (AU‐565 and MCF‐7) associated with loss of cell surface HER‐2/neu antigenMolecular Carcinogenesis, 1990
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986
- Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodiesCell, 1985
- The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF 1Cell, 1985